SGK1

Serine/threonine-protein kinase Sgk1 · O00141 · SGK1 on Sugi Atlas →

18,884 patent compounds predicted against SGK1, 10,363 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1323061	1.00	20/20
SCHEMBL1323489	0.71	20/20
SCHEMBL1323606	0.70	20/20
SCHEMBL1322513	0.69	20/20
SCHEMBL1322557	0.66	19/20
SCHEMBL1324002	0.61	17/20
Hydrochloric Acid (SCHEMBL1062181)	0.42	9/20
Hydrochloric Acid (SCHEMBL1062184)	0.42	9/20
Hydrochloric Acid (SCHEMBL1062185)	0.42	9/20
Hydrochloric Acid (SCHEMBL1062197)	0.39	9/20
Hydrochloric Acid (SCHEMBL1062199)	0.39	9/20
Hydrochloric Acid (SCHEMBL1062201)	0.39	9/20
SCHEMBL1460627	0.55	8/20
SCHEMBL1460752	0.53	7/20
SCHEMBL95455	0.52	7/20
SCHEMBL1460577	0.55	6/20
SCHEMBL793409	0.48	6/20
SCHEMBL423903	0.62	5/20
SCHEMBL95834	0.48	5/20
SCHEMBL1460991	0.47	5/20

Clinical trials — most relevant to SGK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Rapid Effects of Hydrocortisone on Glucose-induced Insulin Secretion in Healthy Humans	PHASE4	COMPLETED
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis	PHASE4	NOT_YET_RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors	PHASE1/PHASE2	NOT_YET_RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
A Study of CS231295 in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Effect of Gene Variants on Dopamine Receptor Natriuretic Responses	PHASE1	UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors	PHASE1	RECRUITING
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy	PHASE1	UNKNOWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Rehabilitation Program in Patients With Acromegaly	nan	UNKNOWN
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Multi-level Molecular Profiling of High Acute Stress: a Clinical Study	nan	UNKNOWN
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Perioperative Glucose Monitoring and Treatment to Reduce Risk of Surgical Site Infections and Complications	nan	ENROLLING_BY_INVITATION
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SGK1 binder may also engage these)

Protein	Name	Similarity
Q6U1I9	—	1.000	Q6U1I9 →
Q9WVC6	—	1.000	Q9WVC6 →
Q4R633	—	1.000	Q4R633 →
Q6GPN6	—	1.000	Q6GPN6 →
Q9XT18	—	1.000	Q9XT18 →
A7MB74	—	1.000	A7MB74 →
Q6GLY8	—	1.000	Q6GLY8 →
Q06226	—	0.999	Q06226 →
Q5Q0U5	—	0.995	Q5Q0U5 →
Q7ZTW4	—	0.995	Q7ZTW4 →
Q5BKK4	—	0.994	Q5BKK4 →
Q8R4U9	—	0.994	Q8R4U9 →
Q8R4V0	—	0.993	Q8R4V0 →
Q9ERE3	—	0.992	Q9ERE3 →
Q6PFQ0	—	0.992	Q6PFQ0 →
SGK3	Serine/threonine-protein kinase Sgk3	0.991	landscape →
A8XNJ6	—	0.991	A8XNJ6 →
A8XJQ6	—	0.990	A8XJQ6 →
RPS6KA1	Ribosomal protein S6 kinase alpha-1	0.990	landscape →
Q5R7A7	—	0.990	Q5R7A7 →
Q9QZS5	—	0.989	Q9QZS5 →
Q63531	—	0.989	Q63531 →
Q5R4K3	—	0.989	Q5R4K3 →
Q5F3L1	—	0.988	Q5F3L1 →
Q2PJ68	—	0.988	Q2PJ68 →
P10665	—	0.987	P10665 →
SGK2	Serine/threonine-protein kinase Sgk2	0.987	landscape →
Q12706	—	0.987	Q12706 →
P18654	—	0.987	P18654 →
RPS6KA5	Ribosomal protein S6 kinase alpha-5	0.987	landscape →